Clinical trial and detection of SARS-CoV-2 by a commercial breath analysis test based on Terahertz technology.

Autor:	De Almeida MB; Paraná Institute of Technology-TECPAR, Curitiba, Paraná State, Brazil., Aharonov-Nadborny R; TeraGroup Terahertz Ltd, Herzliya, Tel Aviv District, Israel., Gabbai E; TeraGroup Terahertz Ltd, Herzliya, Tel Aviv District, Israel., Palka AP; Paraná Institute of Technology-TECPAR, Curitiba, Paraná State, Brazil., Schiavo L; Paraná Institute of Technology-TECPAR, Curitiba, Paraná State, Brazil., Esmanhoto E; Paraná Institute of Technology-TECPAR, Curitiba, Paraná State, Brazil., Riediger I; Paraná State Reference Laboratory, São Jose dos Pinhais, Paraná State, Brazil., Rocha J; Department of Infectious Diseases, Pontifical Catholic University, Curitiba, Paraná State, Brazil., Margulis A; TeraGroup Terahertz Ltd, Herzliya, Tel Aviv District, Israel., Loureiro M; Paraná Institute of Technology-TECPAR, Curitiba, Paraná State, Brazil., Pettan-Brewer C; Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA, United States of America., Kmetiuk LB; Department of Veterinary Medicine, Federal University of Paraná State, Curitiba, Paraná State, Brazil., De Barros-Filho IR; Department of Veterinary Medicine, Federal University of Paraná State, Curitiba, Paraná State, Brazil., Biondo AW; Department of Veterinary Medicine, Federal University of Paraná State, Curitiba, Paraná State, Brazil.
Jazyk:	angličtina
Zdroj:	PloS one [PLoS One] 2022 Sep 20; Vol. 17 (9), pp. e0273506. Date of Electronic Publication: 2022 Sep 20 (Print Publication: 2022).
DOI:	10.1371/journal.pone.0273506
Abstrakt:	Public health threats such as the current COVID-19 pandemics have required prompt action by the local, national, and international authorities. Rapid and noninvasive diagnostic methods may provide on-site detection and immediate social isolation, used as tools to rapidly control virus spreading. Accordingly, the aim of the present study was to evaluate a commercial breath analysis test (TERA.Bio®) and deterministic algorithm for detecting the SARS-CoV-2 spectral signature of Volatile Organic Compounds present in exhaled air samples of suspicious persons from southern Brazil. A casuistic total of 70 infected and 500 non-infected patients were sampled, tested, and results later compared to RT-qPCR as gold standard. Overall, the test showed 92.6% sensitivity and 96.0% specificity. No statistical correlation was observed between SARS-CoV-2 positivity and infection by other respiratory diseases. Further studies should focus on infection monitoring among asymptomatic persons. In conclusion, the breath analysis test herein may be used as a fast, on-site, and easy-to-apply screening method for diagnosing COVID-19. Competing Interests: The authors have declared that no competing interests exist.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu